TECHNOLOGY-ENABLED HEALTH – Digitally Connected Health Technologies: Blazing Meaningful Trails in Healthcare
Daniel Spors and Kyle Dolbow, PhD, say the overall digital health market is currently $76 billion, and is estimated to grow at 21%, and this space includes life sciences and medical device companies that are incorporating digital technology into their products and services, such as smart inhalers and remote therapy devices.
Gordon Bates, Head of Chemical Division at Lonza Pharma & Biotech, shares his perspective about industry needs and how strategic acquisitions are enhancing Lonza’s position as a development and manufacturing partner of choice.
OPHTHALMIC SQUEEZE DISPENSER – Eliminating the Need for Additives in Multidose Preservative-Free Eyecare Formulations
Degenhard Marx, PhD, and Matthias Birkhoff highlight their company’s Ophthalmic Squeeze Dispenser (OSD), a multi-dose dropper that relies solely on mechanical measures to prevent microbial contamination of the bottle content.
Jeff Galvin believes as the pace of gene and cell therapies accelerates over this next decade, potential cures for chronic diseases, cancer cures, and autosomal defect cures will result, and the efficacy of new therapeutics may move as much as $500 billion from traditional pharmaceuticals to gene technologies.
Jason M. LePree, RPh, PhD, reviews the causes of poor bioavailability for drugs and provides an introduction to lipid-based drug delivery systems, and how the formulation approach can be used to overcome impediments to good bioavailability of therapeutic actives.
EXECUTIVE INTERVIEW – Particle Sciences: Experts in Development & Manufacturing of Complex Dosage Forms
Dr. Mark Mitchnick, CEO of Particle Sciences and CMO of Lubrizol, discusses the rise of complex drug products, the capabilities needed to develop and manufacture these products, and the company’s expansion in this area.
SPECIAL FEATURE – Injectable Drug Delivery: New Technologies Deliver Biologics & Differentiate Brands
Contributor Cindy H. Dubin reports on a segment of the drug delivery industry that will see its market revenue double in just 5 years in response to a growing need to deliver highly viscous, high-volume drugs.
Torsten Maschke, CEO of Datwyler Sealing Solutions, speaks about the opportunities and challenges the current healthcare industry poses and how they are met by Datwyler’s strategy and products.
Jeannie Joughin, PhD, asks what does a pharmaceutical company do when everyone wants more effective new therapies but no one – including third-party payers – wants to pay the price for their development? De-risk the drug development process, in every possible way.
PHARMACEUTICAL PACKAGING – How Advances in Pharmaceutical Packaging Are Better Meeting Patients’ Needs
Detlev Haack, PhD, and Martin Koeberle, PhD, says an industry-wide focus on the design of packaging that can protect user-friendly dosage forms, as well as improve patient compliance and fit into modern consumers’ lifestyles, has resulted in a wide range of primary and secondary packaging solutions.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
EXECUTIVE INTERVIEW – Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.